




RealRate

# MEDICINAL PRODUCTS 2022

ARCA biopharma Inc.  
Rank 19 of 51





RealRate

# MEDICINAL PRODUCTS 2022

ARCA biopharma Inc.  
Rank 19 of 51



The relative strengths and weaknesses of ARCA biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ARCA biopharma Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 163% points. The greatest weakness of ARCA biopharma Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 38% points.

The company's Economic Capital Ratio, given in the ranking table, is 82%, being 95% points above the market average of -14%.

Input Variable	Value in 1000 USD
Assets, Current	54,421
Assets, Non-Current	455
General and Administrative Expense	5,503
Goodwill	0
Liabilities, Current	3,498
Liabilities, Non-Current	383
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	0
Other Revenues	13
Property, Plant and Equipment, Net	48
Research and Development	13,832

Output Variable	Value in 1000 USD
Liabilities	3,881
Assets	54,924
Expenses	19,335
Revenues	13
Stockholders Equity	51,043
Net Income	-19,322
Comprehensive Net Income	-19,322
Economic Capital Ratio	82%